

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 July 2022 (28.07.2022)



(10) International Publication Number
WO 2022/159679 A2

- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2022/013279
- (22) **International Filing Date:**
21 January 2022 (21.01.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/139,997 21 January 2021 (21.01.2021) US
63/222,087 15 July 2021 (15.07.2021) US
63/282,001 22 November 2021 (22.11.2021) US
- (71) **Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.** [US/US]; 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).
- (72) **Inventors: ZEKOVIC, Tamara;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **SMITH, Connor;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **GREBACK-CLARKE, Paul;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander

Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **VORST, Eric;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **GRAHAM, Eva;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **SMITH, Jacob;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **BAJROVIC, Irmela;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **HOBBS, Jordan;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **TIKKANEN, Robert;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **GRIEGER, Josh;** c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).

(74) **Agent: BRAICH, Ravinderjit et al.;** Nixon Peabody LLP, Exchange Place, 53 State Street, Boston, Massachusetts 02109 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) **Title:** METHOD FOR PURIFYING RECOMBINANT VIRAL PARTICLES




FIG. 2

(57) **Abstract:** Provided herein are purification, production and manufacturing methods for recombinant viral vector particles such as recombinant adeno-associated viral (rAAV) vector particles substantially free of empty viral particles; a population of recombinant adeno-associated virus (rAAV) particles purified using the method described herein, and a pharmaceutical composition comprising the purified rAAV.

WO 2022/159679 A2

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*